2024³â Ç¥ÀûÄ¡·á¿¬±¸È¸ Ãá°èÇмú´ëȸ : 2024-04-27 |
|
2024³â Ç¥ÀûÄ¡·á¿¬±¸È¸ Ãá°èÇмú´ëȸ : 2024-04-27 ±³À°ÁÖÁ¦ : 2024³â Ç¥ÀûÄ¡·á¿¬±¸È¸ Ãá°èÇмú´ëȸ ÁÖÃÖ±â°ü : ´ëÇÑÆó¾ÏÇÐȸ ´ã´çÀÚ : ±èÀÎÁ¤ À̸ÞÀÏ : kalc@lungca.or.kr ±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ÈäºÎ¿Ü°ú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, Áø´Ü°Ë»çÀÇÇаú, º´¸®°ú Âü¼®¿¹»óÀÎ : 100¸í Áö¿ª : Àü¶ó³²µµ ¼¼ºÎ¼ö°·á : 80,000¿ø ºñ°í »çÀüµî·Ï ȸ¿ø: 50,000¿ø/ ºñȸ¿ø 70,000¿ø ÇöÀåµî·Ï ȸ¿ø: 60,000¿ø/ ºñȸ¿ø 80,000¿ø
±³À°½Ã°£ 03¿ù 16ÀÏ ¿©¼ö¿¢½ºÆ÷ÄÁº¥¼Ç¼¾ÅÍ Cµ¿ 1Ãþ ÄÁÆÛ·±½ºÈ¦ 13:00~13:25 Cause and Mechanism of Tx failure to conventional chemotherapy of NSCLC À̹ÎÇõ(°Ç¾çÀÇ´ë) ±³À°½Ã°£ 03¿ù 16ÀÏ ¿©¼ö¿¢½ºÆ÷ÄÁº¥¼Ç¼¾ÅÍ Cµ¿ 1Ãþ ÄÁÆÛ·±½ºÈ¦ 13:25~13:50 Strategies to overcome chemotherapy failure ÃÖÁÖȯ(°í·ÁÀÇ´ë) ±³À°½Ã°£ 03¿ù 16ÀÏ ¿©¼ö¿¢½ºÆ÷ÄÁº¥¼Ç¼¾ÅÍ Cµ¿ 1Ãþ ÄÁÆÛ·±½ºÈ¦ 13:50~14:15 Cause and Mechanism of Tx failure to TKIs ÀÓÁ¤¿í(°¡Å縯ÀÇ´ë) ±³À°½Ã°£ 03¿ù 16ÀÏ ¿©¼ö¿¢½ºÆ÷ÄÁº¥¼Ç¼¾ÅÍ Cµ¿ 1Ãþ ÄÁÆÛ·±½ºÈ¦ 14:15~14:40 How to overcome (1): Combination with current Tx ¾ÈÁØÈ«(¿µ³²ÀÇ´ë) ±³À°½Ã°£ 03¿ù 16ÀÏ ¿©¼ö¿¢½ºÆ÷ÄÁº¥¼Ç¼¾ÅÍ Cµ¿ 1Ãþ ÄÁÆÛ·±½ºÈ¦ 14:40~15:05 How to overcome (2): Emerging Tx (ADC, Targeted protein degradatio À¯¿ì°æ(ÀÎÇÏÀÇ´ë) ÈÞ½Ä 03¿ù 16ÀÏ ¿©¼ö¿¢½ºÆ÷ÄÁº¥¼Ç¼¾ÅÍ Cµ¿ 1Ãþ ÄÁÆÛ·±½ºÈ¦ 15:05~15:30 Coffee break ( ) ±³À°½Ã°£ 03¿ù 16ÀÏ ¿©¼ö¿¢½ºÆ÷ÄÁº¥¼Ç¼¾ÅÍ Cµ¿ 1Ãþ ÄÁÆÛ·±½ºÈ¦ 15:30~15:55 Cause and Mechanism of Tx failure to conventional therapy of SCLC ±è¼öÇÑ(ºÎ»êÀÇ´ë) ±³À°½Ã°£ 03¿ù 16ÀÏ ¿©¼ö¿¢½ºÆ÷ÄÁº¥¼Ç¼¾ÅÍ Cµ¿ 1Ãþ ÄÁÆÛ·±½ºÈ¦ 15:55~16:25 How to overcome Strategies to overcome small cell lung cancer that has failed frontline treatment ¹ÚÁøÇÑ(ÀÎÁ¦ÀÇ´ë)
|
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù. |
|
Á¦¸ñ |
Ãßõ¼ö : 1 , Á¶È¸¼ö : 521 , ´ñ±Û¼ö : 0 |
Ãßõ¼ö : 0 , Á¶È¸¼ö : 549 , ´ñ±Û¼ö : 0 |
Ãßõ¼ö : 0 , Á¶È¸¼ö : 404 , ´ñ±Û¼ö : 0 |
Ãßõ¼ö : 0 , Á¶È¸¼ö : 528 , ´ñ±Û¼ö : 1 |
Ãßõ¼ö : 0 , Á¶È¸¼ö : 6,062 , ´ñ±Û¼ö : 0 |